Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyBiologicalProcessisoprenoid biosynthetic process

NUS1 BCO1

3.07e-0436152GO:0008299
GeneOntologyBiologicalProcessvascular endothelial growth factor signaling pathway

ADGRA2 NUS1

6.17e-0451152GO:0038084
GeneOntologyBiologicalProcesscellular response to vascular endothelial growth factor stimulus

ADGRA2 NUS1

1.36e-0376152GO:0035924
DomainNPIP

NPIPB5 NPIPB13 NPIPB9 NPIPB3 NPIPB2 NPIPB15

2.75e-1514216IPR009443
Pubmed

The sequence and analysis of duplication-rich human chromosome 16.

NPIPB9 NPIPB3 NPIPB2 NPIPB11

4.28e-079024415616553
Pubmed

Divergent origins and concerted expansion of two segmental duplications on chromosome 16.

NPIPB5 NPIPB3

1.37e-06324211948212
Cytoband16p12.2

NPIPB5 NPIPB3 NPIPB4

9.64e-073724316p12.2
CytobandEnsembl 112 genes in cytogenetic band chr16p11

NPIPB13 NPIPB12 NPIPB9 NPIPB11

1.27e-05278244chr16p11
CytobandEnsembl 112 genes in cytogenetic band chr16p12

NPIPB5 NPIPB3 NPIPB4

9.87e-05172243chr16p12
Cytoband16p11.2

NPIPB13 NPIPB12 NPIPB11

1.35e-0419124316p11.2
CytobandEnsembl 112 genes in cytogenetic band chr16q23

NPIPB15 BCO1

1.68e-03116242chr16q23
CoexpressionJINESH_BLEBBISHIELD_TRANSFORMED_STEM_CELL_SPHERES_DN

NPIPB13 NPIPB12 NPIPB3 NPIPB11 NPIPB15

5.58e-06302235M38975
CoexpressionJINESH_BLEBBISHIELD_VS_LIVE_CONTROL_UP

NPIPB13 NPIPB12 NPIPB3 NPIPB11 NPIPB15

1.69e-05380235M38974
CoexpressionGSE2585_THYMIC_MACROPHAGE_VS_MTEC_UP

PEX10 NOC4L VPS13D GPX4

2.45e-05197234M6279
ToppCellCV-Severe-7|CV / Virus stimulation, Condition and Cluster

NPIPB5 NPIPB3 SFI1 NUS1

2.26e-061762443de0c7d77210049e5616db21eed1490a17a5ec2d
ToppCellCV-Severe-7|Severe / Virus stimulation, Condition and Cluster

NPIPB5 NPIPB3 SFI1 NUS1

2.31e-0617724482fdd6185b368f54f03de389427cbe3071d21a99
ToppCellCV-Mild-7|CV / Virus stimulation, Condition and Cluster

FBXO41 LCORL NPIPB4

1.01e-0417024325ebde7d2f8ae1afdfaf5876284ff20bb179eb10
ToppCellMid-temporal_gyrus_(MTG)|World / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

NPIPB5 NPIPB3 BCO1

1.16e-04178243ad187db4c40b9078d54dd915c143e0172b2f47b8
ToppCellParenchymal-10x3prime_v2-Immune_Lymphocytic-T-T_CD8-CD8_TRM|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations

FBXO41 NPIPB11 NPIPB4

1.28e-0418424317ffa0e890960c00a3b5fa33d48caba66c61dbb0
ToppCelltumor_Lymph_Node_/_Brain-Fibroblasts-Undetermined|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass

NPIPB5 PLEKHH2 TARS2

1.36e-041882438231e635706a296db6b6da1029a33bbc1b52478e
ToppCellsevere-low-quality_cells|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

NPIPB5 SFI1 NPIPB4

1.47e-041932439337bc93e3904c7fc7c93c328518bcd6453b1e8c
ToppCellnucseq-Immune-Lymphocytic_T/NK-Lymphocytic_T/NK-CD4_T|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

NPIPB5 NPIPB3 NPIPB4

1.47e-041932439c9434a3297b85774b4f0ecab6294f44d738e29f
ToppCellnucseq|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

NPIPB5 NPIPB3 NPIPB4

1.47e-04193243779276e775cb2492e8dd36436295a536084a6415
ToppCellmild-low-quality_cells|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

NPIPB5 SFI1 NPIPB4

1.61e-04199243f0b0097df0026496470a80d8cc9375ffd8389b00
DrugEquilin [474-86-2]; Up 200; 15uM; MCF7; HT_HG-U133A

FBXO41 VPS13D SFI1 BCO1

2.62e-051922145620_UP
Drug(S)-(-)-Cycloserine [339-72-0]; Down 200; 39.2uM; MCF7; HT_HG-U133A

XYLT2 FBXO41 VPS13D SFI1

2.90e-051972143870_DN
DrugMethiothepin maleate [19728-88-2]; Down 200; 8.4uM; HL60; HG-U133A

ADGRA2 NOC4L SFI1 TARS2

2.96e-051982141616_DN
DrugLY163892

ADGRA2 BCO1

9.65e-0516212CID000003956
Drug15d-PGJ2; Down 200; 10uM; MCF7; HT_HG-U133A

PEX10 SFI1 NUS1

6.50e-041872136948_DN
Drug15d-PGJ2; Down 200; 10uM; HL60; HT_HG-U133A

FBXO41 ADGRA2 SFI1

6.50e-041872136190_DN
DrugLY 294002; Down 200; 10uM; HL60; HT_HG-U133A

FBXO41 ADGRA2 VPS13D

6.60e-041882136195_DN
DrugMefenamic acid [61-68-7]; Down 200; 16.6uM; MCF7; HT_HG-U133A

FBXO41 VPS13D TARS2

7.23e-041942131699_DN
DrugEtifenin [63245-28-3]; Up 200; 12.4uM; MCF7; HT_HG-U133A

ADGRA2 SFI1 BCO1

7.23e-041942132838_UP
DrugPentylenetetrazole [54-95-5]; Down 200; 29uM; MCF7; HT_HG-U133A

FBXO41 PEX10 SFI1

7.34e-041952132255_DN
DrugAsiaticoside [16830-15-2]; Down 200; 4.2uM; MCF7; HT_HG-U133A

FBXO41 PEX10 VPS13D

7.34e-041952137004_DN
DrugLobelanidine hydrochloride [6112-86-3]; Up 200; 10.6uM; MCF7; HT_HG-U133A

ADGRA2 VPS13D SFI1

7.34e-041952132897_UP
DrugPiracetam [7491-74-9]; Up 200; 28.2uM; MCF7; HT_HG-U133A

ADGRA2 SFI1 BCO1

7.34e-041952132861_UP
DrugFluorometholone [426-13-1]; Down 200; 10.6uM; HL60; HT_HG-U133A

FBXO41 PEX10 VPS13D

7.34e-041952132509_DN
Drugmonastrol; Up 200; 100uM; MCF7; HG-U133A

FBXO41 NOC4L VPS13D

7.34e-04195213681_UP
DrugST021200; Up 200; 10uM; PC3; HT_HG-U133A

XYLT2 VPS13D NUS1

7.34e-041952137559_UP
DrugButylparaben [94-26-8]; Up 200; 20.6uM; MCF7; HT_HG-U133A

FBXO41 ADGRA2 SFI1

7.34e-041952135608_UP
DrugMetrizamide [31112-62-6]; Up 200; 5uM; HL60; HT_HG-U133A

XYLT2 PEX10 NUS1

7.34e-041952131318_UP
Drugradicicol, diheterospora chlamydosporia; Down 200; 0.1uM; HL60; HT_HG-U133A

FBXO41 ADGRA2 PEX10

7.34e-041952131160_DN
Drug3-Acetamidocoumarin [779-30-6]; Up 200; 19.6uM; MCF7; HT_HG-U133A

XYLT2 VPS13D SFI1

7.34e-041952137361_UP
DrugMiconazole [22916-47-8]; Up 200; 9.6uM; MCF7; HT_HG-U133A

FBXO41 ADGRA2 SFI1

7.34e-041952134960_UP
DrugAtractyloside potassium salt [102130-43-8]; Up 200; 5uM; MCF7; HT_HG-U133A

FBXO41 SFI1 BCO1

7.45e-041962133435_UP
Drugfelodipine; Down 200; 10uM; MCF7; HT_HG-U133A_EA

XYLT2 PEX10 SFI1

7.45e-04196213848_DN
DrugDihydroergotoxine mesylate [8067-24-1]; Up 200; 6.4uM; MCF7; HT_HG-U133A

VPS13D SFI1 BCO1

7.45e-041962132793_UP
DrugCP-863187 [668981-07-5]; Up 200; 10uM; PC3; HT_HG-U133A

XYLT2 VPS13D SFI1

7.45e-041962137558_UP
DrugEthotoin [86-35-1]; Down 200; 19.6uM; MCF7; HT_HG-U133A

XYLT2 VPS13D SFI1

7.45e-041962133892_DN
DrugGossypol [303-45-7]; Down 200; 7.8uM; MCF7; HT_HG-U133A

VPS13D SFI1 BCO1

7.45e-041962133637_DN
Drug17-DMAG; Down 200; 0.1uM; HL60; HT_HG-U133A

XYLT2 FBXO41 ADGRA2

7.56e-041972131154_DN
DrugTriflusal [322-79-2]; Down 200; 16.2uM; HL60; HG-U133A

VPS13D SFI1 NUS1

7.56e-041972131717_DN
DrugMethyldopate hydrochloride [2508-79-4]; Down 200; 14.6uM; MCF7; HT_HG-U133A

XYLT2 VPS13D SFI1

7.56e-041972134986_DN
DrugFenspiride hydrochloride [5053-08-7]; Down 200; 13.4uM; MCF7; HT_HG-U133A

FBXO41 VPS13D SFI1

7.56e-041972132269_DN
DrugEtodolac [41340-25-4]; Down 200; 14uM; MCF7; HT_HG-U133A

FBXO41 VPS13D SFI1

7.56e-041972132254_DN
DrugMethyl benzethonium chloride [25155-18-4]; Down 200; 8.6uM; PC3; HT_HG-U133A

XYLT2 VPS13D SFI1

7.56e-041972133768_DN
DrugDosulepin hydrochloride [897-15-4]; Up 200; 12uM; MCF7; HT_HG-U133A

ADGRA2 VPS13D BCO1

7.56e-041972132864_UP
DrugTamoxifen citrate [54965-24-1]; Down 200; 7uM; MCF7; HT_HG-U133A

XYLT2 VPS13D SFI1

7.56e-041972132212_DN
DrugAltretamine [654-05-6]; Down 200; 19uM; HL60; HT_HG-U133A

XYLT2 PEX10 SFI1

7.56e-041972133090_DN
DrugLiothyronine [6893-02-3]; Down 200; 6.2uM; HL60; HT_HG-U133A

XYLT2 PEX10 SFI1

7.56e-041972132984_DN
DrugGinkgolide A [15291-75-5]; Up 200; 9.8uM; HL60; HT_HG-U133A

XYLT2 FBXO41 SFI1

7.56e-041972131324_UP
DrugClopamide [636-54-4]; Down 200; 11.6uM; MCF7; HT_HG-U133A

XYLT2 PEX10 SFI1

7.56e-041972133220_DN
DrugNU1025; Up 200; 100uM; MCF7; HG-U133A

XYLT2 VPS13D SFI1

7.56e-04197213313_UP
Drugraloxifene hydrochloride; Up 200; 0.1uM; MCF7; HG-U133A

XYLT2 PEX10 VPS13D

7.56e-04197213202_UP
DrugConvolamine hydrochloride [500-56-1]; Down 200; 11.8uM; MCF7; HT_HG-U133A

XYLT2 VPS13D SFI1

7.68e-041982132771_DN
DrugEtodolac [41340-25-4]; Down 200; 14uM; MCF7; HT_HG-U133A

PEX10 VPS13D TARS2

7.68e-041982137006_DN
DrugCisapride [81098-60-4]; Up 200; 8.6uM; PC3; HT_HG-U133A

ADGRA2 SFI1 BCO1

7.68e-041982136706_UP
DrugCloxacillin sodium salt [642-78-4]; Down 200; 8.8uM; HL60; HG-U133A

PEX10 VPS13D SFI1

7.68e-041982131443_DN
DrugNadolol [42200-33-9]; Up 200; 13uM; MCF7; HT_HG-U133A

FBXO41 SFI1 BCO1

7.68e-041982133359_UP
DrugEthambutol dihydrochloride [1070-11-7]; Up 200; 14.4uM; HL60; HG-U133A

XYLT2 FBXO41 SFI1

7.68e-041982131981_UP
DrugPhensuximide [86-34-0]; Up 200; 21.2uM; MCF7; HT_HG-U133A

FBXO41 ADGRA2 SFI1

7.68e-041982133521_UP
Drug1,1-dimethylbiguanide hydrochloride; Up 200; 1000uM; MCF7; HG-U133A

FBXO41 NOC4L SFI1

7.68e-041982134_UP
DrugMonensin sodium salt [22373-78-0]; Down 200; 5.8uM; HL60; HT_HG-U133A

PEX10 VPS13D SFI1

7.68e-041982132580_DN
DrugReserpine [50-55-5]; Up 200; 6.6uM; MCF7; HT_HG-U133A

ADGRA2 SFI1 BCO1

7.68e-041982133341_UP
DrugFendiline hydrochloride [13636-18-5]; Down 200; 11.4uM; MCF7; HT_HG-U133A

XYLT2 PEX10 VPS13D

7.68e-041982133190_DN
DrugChenodiol [474-25-9]; Up 200; 10.2uM; MCF7; HT_HG-U133A

XYLT2 FBXO41 SFI1

7.68e-041982137433_UP
DrugKynurenine, 3-hydroxy (R,S) [2147-61-7]; Up 200; 17.8uM; HL60; HT_HG-U133A

FBXO41 VPS13D SFI1

7.68e-041982131300_UP
DrugAminocaproic acid [60-32-2]; Down 200; 30.4uM; MCF7; HT_HG-U133A

XYLT2 PEX10 SFI1

7.68e-041982136501_DN
DrugDicumarol [66-76-2]; Up 200; 11.8uM; PC3; HT_HG-U133A

FBXO41 ADGRA2 SFI1

7.68e-041982134323_UP
Drugraloxifene hydrochloride; Down 200; 0.1uM; ssMCF7; HG-U133A

XYLT2 FBXO41 SFI1

7.68e-04198213376_DN
DrugGlipizide [29094-61-9]; Up 200; 9uM; PC3; HT_HG-U133A

ADGRA2 VPS13D SFI1

7.68e-041982136645_UP
Drughaloperidol; Down 200; 10uM; MCF7; HT_HG-U133A

XYLT2 PEX10 VPS13D

7.79e-041992136923_DN
Drugtetraethylenepentamine pentahydrochloride; Down 200; 100uM; ssMCF7; HG-U133A

NOC4L VPS13D SFI1

7.79e-04199213498_DN
DrugTTNPB; Down 200; 0.1uM; MCF7; HG-U133A

XYLT2 FBXO41 SFI1

7.79e-04199213223_DN
DrugAmprolium hydrochloride [137-88-2]; Up 200; 12.6uM; HL60; HG-U133A

XYLT2 PEX10 NOC4L

7.79e-041992131979_UP
DrugBenzydamine hydrochloride [132-69-4]; Up 200; 11.6uM; MCF7; HT_HG-U133A

FBXO41 VPS13D SFI1

7.79e-041992133169_UP
DrugPizotifen malate [5189-11-7]; Down 200; 9.4uM; MCF7; HT_HG-U133A

XYLT2 VPS13D SFI1

7.79e-041992136513_DN
DrugHaloperidol [52-86-8]; Down 200; 10.6uM; HL60; HG-U133A

VPS13D SFI1 TARS2

7.90e-042002132039_DN
DrugChlormezanone [80-77-3]; Up 200; 14.6uM; HL60; HG-U133A

PEX10 VPS13D SFI1

7.90e-042002131620_UP

Protein segments in the cluster

PeptideGeneStartEntry
FTHHCARRRDVRASW

ADGRA2

1066

Q96PE1
LCNWVRMAAAEHRHS

NPIPB3

211

Q92617
LCNWVRMAAAEHRHS

NPIPB12

211

F8W0I5
RGCSGARRWMRHHTA

PEX10

136

O60683
FRRELDSWRHRLMHC

LCORL

36

Q8N3X6
SCLAAAHHRMRWRAD

NUS1

76

Q96E22
AHHRMRWRADGRSLE

NUS1

81

Q96E22
LCNWVRMAAAEHRHS

NPIPB5

211

A8MRT5
LCNWVRMAAAEHRHS

NPIPB4

211

C9JG80
LCNWVRMAAAEHRHS

NPIPB15

211

A6NHN6
STRWMALRGHSAADC

PLEKHH2

1321

Q8IVE3
LCNWVRMAAAEHRHS

NPIPB11

211

E5RHQ5
HAAEVCRDWRFVARH

FBXO41

571

Q8TF61
SRDDWRCARSMHEFS

GPX4

31

P36969
WMRHRYHSCCNRLGE

NOC4L

91

Q9BVI4
LCNWVRMAAAEHRHS

NPIPB9

226

F8W1W9
LCNWVRMAAAEHRHS

NPIPB13

211

A6NJU9
AHCLMFAHRPRSWRE

TARS2

411

Q9BW92
AHSLHRAVRRCATLW

SFI1

916

A8K8P3
RRMSWASCLAFHREE

BCO1

266

Q9HAY6
RFWEAALLMRHQRCH

ZNF865

856

P0CJ78
LCNWVRMAAAEHRHS

NPIPB2

226

A6NJ64
DRLFHECDSHMWRLG

XYLT2

371

Q9H1B5
MWRDSFMRHRGHCER

ZBTB22

551

O15209
RCTWDFMLHRARDAV

VPS13D

336

Q5THJ4